Flowers for Algernon and CRISPR Technology: Arguing an Unsettling ConnectionClinical Oncology News (blog)The specific science called into question here is the new molecular technology known as CRISPR.2 This relatively simple technique provides the extr… Continue reading
Study Shows Inactive B2M Gene is Recurrent in Lung Cancer and May Condition Response to ImmunotherapyScicasts (press release) (blog)The new immunotherapy treatments aim to block the activity of certain proteins that inhibit the immune system. In lung c… Continue reading
Xconomy |
StemBioSys Taps VWR to Distribute Stem Cell Products in US, Canada
Xconomy San Antonio — StemBioSys has signed a deal to have its stem cell production products distributed in the U.S. and Canada by VWR (NASDAQ: VWR), a distributor of lab products to the life sciences industry, according to CEO Bob Hutchens. StemBioSys had a … |
Phys.Org |
CRISPR meets single-cell sequencing in new screening method
Phys.Org Genome editing using CRISPR/Cas9 “gene scissors” is a powerful tool for biological discovery and for identifying novel drug targets. In pooled CRISPR screens, a large number of cells are edited simultaneously using CRISPR guide-RNAs against thousands … |
EurekAlert (press release) |
CRISPR meets single-cell sequencing in new screening method
EurekAlert (press release) (Vienna, 19 January 2017) Genome editing using CRISPR/Cas9 “gene scissors” is a powerful tool for biological discovery and for identifying novel drug targets. In pooled CRISPR screens, a large number of cells are edited simultaneously using CRISPR … |
FierceBiotech |
Ex-GSK rare disease head moves to Genenta
FierceBiotech He joins Milan, Italy-based Genenta Science, a biotech focused on hematopoietic stem cell gene therapy in cancer, as its new CMO. Russo has worked on gene therapy before as he was head of R&D at London-based GSK’s rare disease unit, helping get its … |
FierceBiotech |
Ex-GSK rare disease head moves to Genenta
FierceBiotech He joins Milan, Italy-based Genenta Science, a biotech focused on hematopoietic stem cell gene therapy in cancer, as its new CMO. Russo has worked on gene therapy before as he was head of R&D at London-based GSK’s rare disease unit, helping get its … |
|
Abeona Therapeutics (ABEO) ABO-101 Gene Therapy Gains Orphan Drug Status in EU
StreetInsider.com Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation (EMA/OD/226/16) for Abeona’s gene therapy program ABO-101 for … |